Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium Supplementation for Hypomagnesemia in CKD
NCT02216877Phase 2Completed
- Sponsor
- Zealand University Hospital
- Start
- Aug 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Mablet in hypomagnesemia (3 arms), sponsored by Zealand University Hospital. Primary endpoint: Intracellular magnesium at 8 weeks. Started Aug 2014; status: completed.
02
Drugs
Mablet
03
Conditions
hypomagnesemia
Beyond the preview
Go deeper on NCT02216877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02216877.